Navco Pharmaceuticals Inc.
NAV.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 97.50K | 89.60K | 268.40K | 185.90K | 567.60K |
| Depreciation & Amortization | 500.00 | 25.50K | 20.00K | 8.10K | 8.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 98.00K | 115.10K | 288.40K | 193.90K | 575.70K |
| Operating Income | -98.00K | -115.10K | -288.40K | -193.90K | -575.70K |
| Income Before Tax | -642.70K | -129.70K | -294.10K | -199.90K | 995.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -642.70K | -129.70K | -294.10K | -199.90K | 995.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -642.70K | -129.70K | -294.10K | -199.90K | 995.50K |
| EBIT | -98.00K | -115.10K | -288.40K | -193.90K | -575.70K |
| EBITDA | -86.60K | -92.20K | -271.00K | -188.50K | -567.60K |
| EPS Basic | -0.01 | 0.00 | -0.01 | -0.01 | 0.02 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | -0.01 | 0.00 | -0.01 | -0.01 | 0.02 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 57.11M | 55.42M | 53.73M | 40.35M | 40.35M |
| Average Diluted Shares Outstanding | 57.11M | 55.42M | 53.73M | 40.35M | 40.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
